296 related articles for article (PubMed ID: 35760093)
1. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
2. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
[TBL] [Abstract][Full Text] [Related]
3. Tactics with Prebiotics for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease via the Improvement of Mitophagy.
Tsuji A; Yoshikawa S; Ikeda Y; Taniguchi K; Sawamura H; Morikawa S; Nakashima M; Asai T; Matsuda S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982539
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
[TBL] [Abstract][Full Text] [Related]
6. White adipose tissue in metabolic associated fatty liver disease.
Zhu X; Zeng C; Yu B
Clin Res Hepatol Gastroenterol; 2024 May; 48(5):102336. PubMed ID: 38604293
[TBL] [Abstract][Full Text] [Related]
7. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
8. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies.
Qu W; Ma T; Cai J; Zhang X; Zhang P; She Z; Wan F; Li H
Front Med (Lausanne); 2021; 8():761538. PubMed ID: 34746195
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
12. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
Khanmohammadi S; Ramos-Molina B; Kuchay MS
Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
[TBL] [Abstract][Full Text] [Related]
13. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease.
Yan S; Zhang S; Du A; Miao H; Lu B; Huang Z; Ji L
Phytomedicine; 2021 Oct; 91():153666. PubMed ID: 34339944
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
Sotoudeheian M
Protein Pept Lett; 2024 May; ():. PubMed ID: 38715329
[TBL] [Abstract][Full Text] [Related]
15. The microbial metabolome in metabolic-associated fatty liver disease.
Li M; Rajani C; Zheng X; Jia W
J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease].
Liu YC; Zhang Y; Qin SC; Xue JL
Sheng Li Xue Bao; 2023 Oct; 75(5):682-690. PubMed ID: 37909139
[TBL] [Abstract][Full Text] [Related]
17. Role of Insulin Resistance in MAFLD.
Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
19. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
20. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]